Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Yue Wei, Hong Zheng, Pamela Lockyer, Naran Bao, Faezeh Darbaniyan, Ziyi Li, Rashmi Kanagal-Shamanna, Kelly A. Soltysiak, Hui Yang, Irene Ganan-Gomez, Kim-Anh Do, Simona Colla, Kelly S. Chien, Guillermo Montalban-Bravo, Naval Daver, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 3664.

https://doi.org/10.1182/blood-2021-150811

Published: 2021

Journal Articles

Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis

Shehab Fareed Mohamed, Tareq Abuasba, Kelly S. Chien, Guillermo Montalban-Bravo, Faezeh Darbaniyan, Sherry A. Pierce, Kelly A. Soltysiak, Fadi Haddad, David McCall, Branko Cuglievan, Elias J. Jabbour, Naval Daver, Tapan M. Kadia, Naveen Pemmaraju, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2021) 138 (Supplement 1): 3687.

https://doi.org/10.1182/blood-2021-149018

Published: 2021

Journal Articles

Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML

Faezeh Darbaniyan, Caleb Class, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Marcos Estecio, Yue Lu, Kelly A. Soltysiak, Kelly S. Chien, Hui Yang, Koji Sasaki, Irene Ganan-Gomez, Simona Colla, Kim-Anh Do, Guillermo Garcia-Manero, Yue Wei

Blood (2021) 138 (Supplement 1): 4652.

https://doi.org/10.1182/blood-2021-153698

Published: 2021

Journal Articles

Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam Borthakur, MD, Kiran Naqvi, MD MPH, Naval Daver, MD, Guillermo Montalban Bravo, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Yesid Alvarado, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly A. Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-140521

Published: 2020

Journal Articles

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-141411

Published: 2020

Journal Articles

Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R

Faezeh Darbaniyan, PhD, Guillermo Montalban Bravo, MD, Yue Wei, PhD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Kim-Anh Do, PhD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-140029

Published: 2020

Journal Articles

Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia

Guillermo Montalban Bravo, MD, Faezeh Darbaniyan, PhD, Rashmi Kanagal-Shamanna, MD, Irene Ganan-Gomez, PhD, Koji Sasaki, MD, Kiran Naqvi, MD MPH, Yue Wei, PhD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-137702

Published: 2020

Journal Articles

Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Faezeh Darbaniyan, PhD, Irene Ganan-Gomez, PhD, Koji Sasaki, MD, Kiran Naqvi, MD MPH, Yue Wei, PhD, Hui Yang, MD PhD, Kelly A. Soltysiak, PhD, Kelly S. Chien, MD, Carlos E. Bueso-Ramos, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139983

Published: 2020

Journal Articles

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-141100

Published: 2020

Journal Articles

Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban Bravo, MD, Koji Sasaki, MD, Carlos E. Bueso-Ramos, MD PhD, Elias Jabbour, MD, Yue Wei, PhD, Faezeh Darbaniyan, PhD, Mark Routbort, MD PhD, Sherry A. Pierce, BSN, BA, Kelly A. Soltysiak, PhD, Keyur Patel, MD PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141446

Published: 2020

NARROW

Inhibition of MDM2 Improves the Therapeutic Effect of Hypomethylating Agents in Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Characteristics and Outcomes of Adolescent and Young Adult (AYA) Patients with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML): A Single-Center Retrospective Analysis

Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML

Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome

Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis

Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R

Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia

Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)

Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy

Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only